<DOC>
	<DOC>NCT00529100</DOC>
	<brief_summary>Measure the 1 year survival of non small cell lung cancer (NSCLC) patients who are being treated with pemetrexed in combination with cisplatin and radiation.</brief_summary>
	<brief_title>Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Some of the requirements to be in this study are: Patient must be at least 18 years old. Patient must have been diagnosed with nonsmall cell lung cancer. Patient must be able to visit the doctor's office once a week. Patient must have adequate blood, liver, lungs and kidney function within the requirements of this study. Female patients of childbearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. Male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug. Patients cannot participate in this study for any of the following reasons: Patient has previously had chemotherapy. Patient has previously had thoracic radiation therapy. Patient has received treatment within the last 30 days with a drug that has not received approval by Health Canada for any indication at the time of study entry. Female patient is pregnant or breastfeeding. Patient is unsuitable to participate in the study in the opinion of the investigator. Patient is unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>